Don't Rule Out Sulfonylureas for Type 2 Diabetes

January 2018

All the hype and TV ads about new drugs for type 2 diabetes will raise questions about the role of sulfonylureas.

The spotlight has been on Jardiance (empagliflozin), Invokana (canagliflozin), and Victoza (liraglutide)...since there's evidence they reduce CV risk in diabetes patients with CV disease or at high CV risk.

Plus they have a low hypoglycemia risk and may lead to weight loss.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: MD includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote